Khalid Islam is an entrepreneur and businessperson who founded 6 companies, among them: Gain Therapeutics, Inc., Sirius Healthcare Partners GmbH and BioAim LLC and who has been at the helm of 13 different companies. Currently, he is Chairman of Fennec Pharmaceuticals, Inc., Chairman at Minoryx Therapeutics SL, Chairman at Gain Therapeutics, Inc. (which he founded in 2017), Chairman for GT Gain Therapeutics SA (a subsidiary of Gain Therapeutics, Inc.), Managing Director at Life Sciences Management GmbH (which he founded in 2014) and Partner at Sirius Healthcare Partners GmbH (which he founded in 2009). Khalid Islam is also on the board of Processa Pharmaceuticals, Inc. and Elion Oncology, Inc. and Advisor at Kurma Biofund FCPR.
Dr. Islam previously was Chairman at Caerus Consulting AS, Chairman at Ki Consulting AG (he founded the company in 2010), Chairman of Arpida, Inc., Chairman of Pcovery ApS, Chairman for Adenium Biotech ApS, Chairman at Adenium AB, Chairman & Chief Executive Officer of Gentium Srl, President, Chief Executive Officer & Director at Arpida AG, Head-Biotechnology at Marion Merrell Dow (Europe) AG, Team Leader & Manager-Alliance at Hoechst Marion Roussel Group and Professor at the University of Milan.
Dr. Islam received an undergraduate degree from Chelsea College and a doctorate from Imperial College London.